Stokes Capital Advisors LLC Sells 1,550 Shares of Colgate-Palmolive (NYSE:CL)

Stokes Capital Advisors LLC lowered its position in shares of Colgate-Palmolive (NYSE:CL) by 2.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 74,410 shares of the company’s stock after selling 1,550 shares during the quarter. Colgate-Palmolive comprises approximately 2.0% of Stokes Capital Advisors LLC’s portfolio, making the stock its 21st biggest position. Stokes Capital Advisors LLC’s holdings in Colgate-Palmolive were worth $7,221,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. E Fund Management Hong Kong Co. Ltd. bought a new position in shares of Colgate-Palmolive during the second quarter worth $25,000. Union Savings Bank grew its position in Colgate-Palmolive by 76.6% in the 4th quarter. Union Savings Bank now owns 309 shares of the company’s stock valued at $25,000 after acquiring an additional 134 shares during the last quarter. PSI Advisors LLC boosted its stake in shares of Colgate-Palmolive by 4,971.4% during the first quarter. PSI Advisors LLC now owns 355 shares of the company’s stock valued at $32,000 after purchasing an additional 348 shares during the period. Atlantic Edge Private Wealth Management LLC bought a new position in shares of Colgate-Palmolive in the fourth quarter worth about $32,000. Finally, Core Wealth Advisors Inc. increased its stake in Colgate-Palmolive by 56.6% in the 4th quarter. Core Wealth Advisors Inc. now owns 404 shares of the company’s stock worth $32,000 after buying an additional 146 shares during the period. Institutional investors own 80.41% of the company’s stock.

Colgate-Palmolive Price Performance

NYSE:CL traded up $0.55 during mid-day trading on Friday, reaching $101.99. 3,172,690 shares of the stock were exchanged, compared to its average volume of 4,407,037. The company has a current ratio of 1.06, a quick ratio of 0.28 and a debt-to-equity ratio of 16.90. The business has a fifty day moving average price of $98.29 and a 200 day moving average price of $92.30. Colgate-Palmolive has a 1-year low of $67.62 and a 1-year high of $104.15. The firm has a market capitalization of $83.68 billion, a PE ratio of 32.28, a PEG ratio of 3.54 and a beta of 0.39.

Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings results on Friday, July 26th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $0.04. The company had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $5 billion. Colgate-Palmolive had a return on equity of 470.19% and a net margin of 14.21%. The firm’s revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.77 earnings per share. Research analysts expect that Colgate-Palmolive will post 3.57 earnings per share for the current fiscal year.

Colgate-Palmolive Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, August 15th. Shareholders of record on Friday, July 19th were given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.96%. The ex-dividend date was Friday, July 19th. Colgate-Palmolive’s dividend payout ratio is 63.29%.

Analyst Upgrades and Downgrades

CL has been the topic of a number of research reports. Royal Bank of Canada raised their target price on shares of Colgate-Palmolive from $88.00 to $95.00 and gave the company a “sector perform” rating in a research report on Monday, April 29th. Morgan Stanley boosted their price target on shares of Colgate-Palmolive from $103.00 to $111.00 and gave the stock an “overweight” rating in a report on Monday, July 29th. Deutsche Bank Aktiengesellschaft boosted their price objective on Colgate-Palmolive from $104.00 to $107.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. Wells Fargo & Company lifted their target price on shares of Colgate-Palmolive from $92.00 to $97.00 and gave the company an “equal weight” rating in a report on Wednesday, July 10th. Finally, Hsbc Global Res downgraded shares of Colgate-Palmolive from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. Eight analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $101.11.

Insider Transactions at Colgate-Palmolive

In other news, EVP Gregory Malcolm sold 10,533 shares of the business’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $103.10, for a total transaction of $1,085,952.30. Following the transaction, the executive vice president now owns 10,377 shares in the company, valued at approximately $1,069,868.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, insider Sally Massey sold 15,850 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $103.28, for a total value of $1,636,988.00. Following the sale, the insider now owns 13,942 shares of the company’s stock, valued at $1,439,929.76. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Gregory Malcolm sold 10,533 shares of Colgate-Palmolive stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $103.10, for a total value of $1,085,952.30. Following the sale, the executive vice president now directly owns 10,377 shares in the company, valued at $1,069,868.70. The disclosure for this sale can be found here. Insiders have sold a total of 41,177 shares of company stock worth $4,245,835 in the last 90 days. 0.34% of the stock is owned by insiders.

Colgate-Palmolive Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.